The Life Sciences Report

Other Streetwise Reports

The Gold Report The Energy Report The Life Sciences Report The Mining Report

Today's Featured Company

Omeros Corp.: (OMER:NASDAQ) Omeros Corp. is a clinical-stage biopharmaceutical company discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Lead drug product Omidria (OMS302) for lens replacement surgery is under review for marketing approval by both FDA and the European Medicines Agency, with U.S. commercial launch planned for H2/14. More >

Streetwise Expert Interviews

Better, Faster, Cheaper—You Can Have All Three in Medtech: Ben Haynor

Given that medical technology is an easy target for payers looking to cut reimbursements, it's important for investors to find device and diagnostic companies with the greatest efficiencies. Accuracy, speed and economy command a premium multiple because these features ultimately relieve pressure on margins, improve quality and reduce patient risk and institutional liability. In this interview with The Life Sciences Report, Senior Research Analyst Ben Haynor of Feltl & Co. shares his top two medtech names, which he expects will achieve outsized gains this year. He also delivers a couple of bonus names that investors could parlay into a profitable small- and micro-cap portfolio. (3/5/14) More >

Shining a Light on Overlooked and Underfollowed Biotechs: George Zavoico

Prospecting for hidden biotech gems makes sense, says H.C. Wainwright & Co. Managing Director George Zavoico, who recently joined the firm's healthcare equity research team. The digging can be hard, but the rewards of successful diligence are huge. In this interview with The Life Sciences Report, Zavoico takes readers on a discovery tour that follows clinical trial data to new ideas that could bring windfalls to portfolios down the road. (3/6/14) More >

Newsletter Briefs

"Behind Omidria, OMER has a robust pipeline that has advanced into a number of phase 1 and phase 2 trials." (3/6/14) Omeros Corp. - The Life Sciences Report Interview with George Zavoico More >

"PSTI's ability to vary the cell phenotype for a specific therapy is unique in the regenerative medicine space." (3/6/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with George Zavoico More >

"The fact that CGIX was able to get a practiced sales force to take its products to market is a very big deal." (3/5/14) Cancer Genetics Inc. - The Life Sciences Report Interview with Ben Haynor More >

"The reward that CUR offers to investors far outweighs the risk." (2/28/14) Neuralstem Inc. - J. Kenser, Seeking Alpha More >

"NEO is in the process of launching next-generation sequencing for the clinical trial market; the deal with Covance sets the stage for the company to go to the next level." (2/27/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Debjit Chattopadhyay More >

"PSTI's timing to explore treatment options for preeclampsia could not be better." (2/26/14) Pluristem Therapeutics Inc. - Sharon di Stefano, Seeking Alpha More >

"AMBS will exercise outstanding warrants that will deliver +$3M." (2/18/14) Amarantus BioScience Holdings Inc. - Jason Napodano, Seeking Alpha More >

"The upside is enormous if NBS can prove its pipeline successful." (2/24/14) NeoStem Inc. - Brian Nichols, Seeking Alpha More >

Expert Analysis

"NEO could generate $5.5–12M for FY/15 and FY/16 from its Covance deal." (3/4/14) NeoGenomics Laboratories - Debjit Chattopadhyay, Emerging Growth Stocks More >

"We expect important OPK catalysts over the next six months." (3/4/14) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >

"Preclinical pharmacokinetic data for OPK's FVIIa-CTP are encouraging." (2/28/14) OPKO Health Inc. - Eun Yang, Jefferies & Co. More >

"MSB finished 2013 with ample cash and just received pivotal FDA approval for its Resvascor trial." (2/26/14) Mesoblast Ltd. - Jason Kolbert, Maxim Group More >

"MSB represents a stock with high near-term potential that many have overlooked." (2/26/14) Mesoblast Ltd. - Kevin DeGeeter, Ladenburg Thalmann More >

"NEO reported record revenue for Q4/13, the highest in its history." (2/20/14) NeoGenomics Laboratories - Grant Zeng, Zacks Small-Cap Research More >

"SNGX is on track to advance multiple clinical programs." (2/18/14) Soligenix Inc. - Grant Zeng, Zacks Small-Cap Research More >

"We feel very confident about each of OPK's diagnostic programs." (2/18/14) OPKO Health Inc. - Charley Jones, Barrington Research More >